News

UrgentRx raises $17.5 million in capital, names former Adams Respiratory CEO chairman

BY Michael Johnsen

DENVER — UrgentRx on Thursday announced that it has closed on $17.5 million of Series C growth capital. An undisclosed family office led the round along with participation from previous investors including Sam Zell, David Bonderman, Randall Kaplan/JUMP Investors and Boulevard Capital Management. The financing will be primarily used to support additional distribution opportunities as well as fund a national marketing campaign.
 
“Our goal at UrgentRx is to offer consumers the easiest and fastest solution for relief of whatever ails them, whenever and wherever it occurs,” stated Jordan Eisenberg, CEO UrgentRx. “UrgentRx Fast Powders are answering an unmet consumer need, providing the most convenient and fast relief available in the market. This infusion of capital gives us the resources to expand into new markets, launch innovative new products, and invest in national marketing to build increased awareness with consumers while supporting our retail partners.”
 
In conjunction with the capital raise, Michael Valentino, former CEO of Adams Respiratory Therapeutics, manufacturer of Mucinex and Delsym, will become chairman of the board. Valentino, a veteran of the OTC pharmaceutical industry, has been a member of the UrgentRx board of directors since July 2013. Under his leadership, Adams grew to over $450 million in annual revenue and was acquired by Reckitt Benckiser for approximately $2.3 billion in January 2008.
 
“There are few executives out there who have the track record and know our industry as well as Mike Valentino. I look forward to working even more closely with him as we continue to rapidly expand the UrgentRx brand,” Eisenberg said.
 
“As demonstrated by impressive retail acceptance and a rapid and efficient capital raise, UrgentRx is now ready and well-positioned to bring the consumer marketplace much-needed innovation for the OTC aisle,” Valentino said. “Today’s consumer tastes and preferences are always adjusting. More than ever before, their lifestyles require medications that can provide convenient, on-the-go relief. UrgentRx delivers on that promise better than anything else in the category.”
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

GoJo Industries issues Purell Advanced 30-Day Challenge to consumers

BY Michael Johnsen

AKRON, Ohio — GoJo Industries, the makers of Purell Advanced Hand Sanitizer, on Wednesday challenged consumers to adopt 30 days of healthy habits by joining the Purell Advanced 30-Day Challenge.
 
"Hand hygiene is one of most important preventative measures you can take to reduce the risk of illness and infection," stated Seth Taylor, brand manager, Purell Consumer. "The 30-Day Challenge is designed to provide families with a fun way to develop hand hygiene habits that can help keep both parents and kids healthy all year long. Studies show that using Purell Advanced Hand Sanitizer three times a day for 30 days can help reduce the risk of getting sick."
 
The 30-Day Challenge asks participants to pledge to use Purell Advanced Hand Sanitizer three times a day and participate in daily challenges, which include posting videos of using Purell products at summer barbeques or showing pictures of your favorite scented formulas, for 30 consecutive days during the promotional period, which began Monday, July 14, 2014, and runs through Sunday, Sept. 14, 2014.
 
Consumers can register for the promotion and download a list of challenges from either the Purell Facebook Page Promotion app or the website, Purell.com/30daychallenge. All completed challenges are submitted via the promotion's website. Participants can also share the promotion and their challenges with friends via email, Facebook, Twitter, Pinterest and Google+ for more chances to win prizes.
 
Winners will be selected through random drawings. Daily winners will receive Purell Advanced products; weekly winners will receive a $100 Visa gift card; and 30 Grand Prize winners will receive a Healthy Family Prize Pack.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

FDA approves new dosage strength of Purdue Pharma’s Butrans

BY Ryan Chavis

STAMFORD, Conn. — Purdue Pharma announced that the Food and Drug Administration approved a new 7.5-mcg/hour dosage strength of Butrans (buprenorphine) transdermal system CIII, which brings the total strengths of the drug to five. Other dosage strengths include 5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour.

The system also is approved to allow use of two patches to help with dose adjustments during titration, the company said, adding that the total dose from both patches shouldn't exceed 20 mcg/hour. Purdue expects to launch the new dosage strength in the United States in October 2014.

"This approval provides healthcare professionals another option to tailor Butrans therapy to the individual needs of appropriate chronic pain patients," said Todd Baumgartner, M.D., MPH, VP research and development and chief medical officer at Purdue Pharma L.P. "The introduction of the 7.5-mcg/hour dosage strength further demonstrates Purdue's ongoing commitment to the management of chronic pain."

Butrans is used for the management of pain that's severe enough to require daily, long-term opioid treatment. Because of the risks of addiction, as well as abuse and misuse with opioids, the company noted that Butrans should be reserved for patients whose alternative treatment options have proven ineffective or not tolerated, or would be "otherwise inadequate to provide sufficient management of pain."
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?